Competitors Pfizer and Catalim are taking distinct clinical paths with their GDF-15 inhibitors. Pfizer is focused squarely on the cachexia endpoint of weight gain. In contrast, Catalim is pursuing a combination strategy with PD-1 inhibitors to demonstrate both cachexia improvement and resensitization of treatment-refractory tumors.

Despite being considered an 'immune desert' unresponsive to checkpoint inhibitors, germ cell tumors may respond to bi-specific T-cell engagers. These drugs, like one targeting Claudin-6 and CD3, physically bring T-cells to the tumor, potentially bypassing the tumor's inherent immune resistance mechanisms like MHC complex downregulation.

The drug exhibits a multimodal mechanism. It not only reverses chemoresistance and halts tumor growth but also 'turns cold tumors hot' by forcing cancer cells to display markers that make them visible to the immune system. This dual action of direct attack and immune activation creates a powerful synergistic effect.

An innovative strategy for solid tumors involves using bispecific T-cell engagers to target the tumor stroma—the protective fibrotic tissue surrounding the tumor. This novel approach aims to first eliminate this physical barrier, making the cancer cells themselves more vulnerable to subsequent immune attack.

Injecting a genetic medicine into one tumor can trigger an 'abscopal response,' where the immune system learns to recognize the cancer. This educated immune system then travels throughout the body to find and destroy other metastatic tumors, even those in deep organs like the lungs, which are typically the fatal ones.

Instead of focusing solely on T-cells, Create's platform first targets myeloid cells, which constitute up to 60% of some solid tumors. Programming these cells transforms the tumor microenvironment, enabling a 5-10x influx of CD8 T-cells. This overcomes a key barrier for T-cell therapies in solid tumors.

A clinical trial using an antibody to block GDF-15, a hormone that signals energetic stress and causes nausea in cancer patients, resulted in double the mortality rate. This suggests that overriding the body's natural, protective 'feel bad' signals can be profoundly dangerous.

To combat immunosuppressive "cold" tumors, new trispecific antibodies are emerging. Unlike standard T-cell engagers that only provide the primary CD3 activation signal, these drugs also deliver the crucial co-stimulatory signal (e.g., via CD28), ensuring full T-cell activation in microenvironments where this second signal is naturally absent.

Recent findings from the AACR conference show a trend away from discovering new T-cell function-promoting targets. Instead, researchers are focusing on novel targets that alter the tumor microenvironment, such as breaking down collagen or repolarizing immune cells, to make existing therapies like checkpoint inhibitors more effective.